BackChina Regenerative Medicine International Limited Overview
China Regenerative Medicine International Limited

China Regenerative Medicine International Limited Return on Equity

China Regenerative Medicine International Limited (8158.HK) has a ROE of 52.59%, above the Healthcare sector average of 13.1%.

Get informed when a big investor buys or sells

+ Follow

ROE

52.59%

Return on Equity

52.59%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

China Regenerative Medicine International Limited (8158.HK) FAQ

China Regenerative Medicine International Limited (8158.HK) currently reports a ROE of 52.59%. That is above the Healthcare sector average of 13.1%. Use the charts on this page to explore China Regenerative Medicine International Limited's ROE history and peer comparisons.

China Regenerative Medicine International Limited's ROE of 52.59% is higher than the Healthcare sector average of 13.1%. That is roughly 301.4% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but China Regenerative Medicine International Limited's current 52.59% should be judged against Healthcare norms (sector average: 13.1%) and against 8158.HK's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 52.59%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.1%. From there, open related valuation or income-statement pages for China Regenerative Medicine International Limited, and consider following 8158.HK for alerts when major investors trade the stock.

China Regenerative Medicine International Limited is classified in the Healthcare sector. On ROE, it currently shows 52.59% versus a sector average near 13.1%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing 8158.HK with unrelated industries.